{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:11Z","timestamp":1787020751343,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFC2702000"],"award-info":[{"award-number":["2021YFC2702000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271838"],"award-info":[{"award-number":["82271838"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800438"],"award-info":[{"award-number":["81800438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300774"],"award-info":[{"award-number":["82300774"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic juvenile idiopathic arthritis (sJIA) is a severe form of juvenile arthritis that is characterized by chronic joint inflammation and systemic symptoms such as fever, rash, and organ involvement. Anti-IL-6 receptor monoclonal antibody tocilizumab is an effective treatment. However, some patients still experience persisting or recurrent symptoms and the real-world effectiveness of canakinumab in Chinese patients with sJIA has never been reported. Therefore, this study aimed to assess the efficacy and safety of canakinumab in Chinese patients with sJIA using real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study on children with active sJIA. Clinical features, laboratory data, corticosteroid dosage, and adverse events (AEs) were collected at baseline and at 4, 8, 12, and 24\u00a0weeks after initiating canakinumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven female and four male patients were included in the study. All patients had previously been treated with tocilizumab and were administered canakinumab for 12.4\u2009\u00b1\u20093.4\u00a0months. Notably, significant improvements were observed in both clinical signs and symptoms as well as laboratory indicators. Four children under corticosteroid treatment were able to successfully discontinue their corticosteroid therapy: one at week 4, two at week 12, and one at week 24. Notably, there was a significant reduction in the number of tender and swollen joints (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0059) as well as the systemic juvenile arthritis disease activity score (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The most common AE was infection, but no patients experienced serious AEs. No cases of macrophage activation syndrome or death were reported during the follow-up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Canakinumab was found to be potentially efficacious and safe in Chinese patients with sJIA. No new AEs were observed with canakinumab treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-024-00974-4","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:02:21Z","timestamp":1710820941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience"],"prefix":"10.1186","volume":"22","author":[{"given":"Lingzhi","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-9390","authenticated-orcid":false,"given":"Haiguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"974_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557\u201367.","journal-title":"Arthritis Rheum"},{"key":"974_CR2","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/DDDT.S114532","volume":"12","author":"N Toplak","year":"2018","unstructured":"Toplak N, Blazina \u0160, Av\u010din T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Devel Ther. 2018;12:1633\u201343.","journal-title":"Drug Des Devel Ther"},{"key":"974_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clim.2015.04.018","volume":"159","author":"N Bruck","year":"2015","unstructured":"Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol. 2015;159:72\u201383.","journal-title":"Clin Immunol"},{"key":"974_CR4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasigli\u00e8 D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505\u201315.","journal-title":"Arthritis Rheum"},{"key":"974_CR5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479\u201386.","journal-title":"J Exp Med"},{"key":"974_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00393-020-00779-2","volume":"79","author":"D F\u00f6ll","year":"2020","unstructured":"F\u00f6ll D, Wittkowski H, Hinze C. Still\u2019s disease as biphasic disorder: current knowledge on pathogenesis and novel treatment approaches. Z Rheumatol. 2020;79:639\u201348.","journal-title":"Z Rheumatol"},{"key":"974_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3389\/fphar.2016.00467","volume":"7","author":"G Giancane","year":"2016","unstructured":"Giancane G, Minoia F, Dav\u00ec S, Bracciolini G, Consolaro A, Ravelli A. IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016;7:467.","journal-title":"Front Pharmacol"},{"key":"974_CR8","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66:1034\u201343.","journal-title":"Arthritis Rheumatol"},{"key":"974_CR9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","volume":"66","author":"PA Nigrovic","year":"2014","unstructured":"Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66:1405\u201313.","journal-title":"Arthritis Rheumatol"},{"key":"974_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","volume":"19","author":"G Horneff","year":"2017","unstructured":"Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19:256.","journal-title":"Arthritis Res Ther"},{"key":"974_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.39407","volume":"68","author":"AA Grom","year":"2016","unstructured":"Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016;68:218\u201328.","journal-title":"Arthritis Rheumatol"},{"key":"974_CR12","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406.","journal-title":"N Engl J Med"},{"key":"974_CR13","first-page":"668","volume":"36","author":"E Feist","year":"2018","unstructured":"Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, et al. Efficacy and safety of canakinumab in patients with Still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668\u201375.","journal-title":"Clin Exp Rheumatol"},{"key":"974_CR14","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","volume":"77","author":"N Ruperto","year":"2018","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77:1710\u20139.","journal-title":"Ann Rheum Dis"},{"key":"974_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/14397595.2020.1783163","volume":"31","author":"K Nishimura","year":"2021","unstructured":"Nishimura K, Hara R, Umebayashi H, Takei S, Iwata N, Imagawa T, et al. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients. Mod Rheumatol. 2021;31:226\u201334.","journal-title":"Mod Rheumatol"},{"key":"974_CR16","unstructured":"Label and approval history for Ilaris. Washington (DC): FDA; 2014. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/#apphist."},{"key":"974_CR17","unstructured":"European public assessment report (EPAR) for Ilaris. Brussels: European Medicines Agency; 2016. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilaris."},{"key":"974_CR18","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"974_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","volume":"146","author":"A Ravelli","year":"2005","unstructured":"Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598\u2013604.","journal-title":"J Pediatr"},{"key":"974_CR20","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/rheumatology\/keaa240","volume":"59","author":"J Tibaldi","year":"2020","unstructured":"Tibaldi J, Pistorio A, Aldera E, Puzone L, El Miedany Y, Pal P, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59:3505\u201314.","journal-title":"Rheumatology (Oxford)"},{"key":"974_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13075-016-1212-x","volume":"19","author":"AH Brachat","year":"2017","unstructured":"Brachat AH, Grom AA, Wulffraat N, Brunner HI, Quartier P, Brik R, et al. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther. 2017;19:13.","journal-title":"Arthritis Res Ther"},{"key":"974_CR22","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/art.41436","volume":"72","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Quartier P, Alexeeva E, Constantin T, Kon\u00e9-Paut I, Marzan K, et al. Efficacy and safety of canakinumab in patients with systemic juvenile idiopathic arthritis with and without fever at baseline: results from an open-label, active-treatment extension study. Arthritis Rheumatol. 2020;72:2147\u201358.","journal-title":"Arthritis Rheumatol"},{"key":"974_CR23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/mr\/roac128","volume":"33","author":"N Iwata","year":"2023","unstructured":"Iwata N, Nishimura K, Hara R, Imagawa T, Shimizu M, Tomiita M, et al. Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: results from an open-label phase III study. Mod Rheumatol. 2023;33:1162\u201370.","journal-title":"Mod Rheumatol"},{"key":"974_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.41612","volume":"73","author":"M Pardeo","year":"2021","unstructured":"Pardeo M, Rossi MN, Pires Marafon D, Sacco E, Bracaglia C, Passarelli C, et al. Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73:1053\u201361.","journal-title":"Arthritis Rheumatol"},{"key":"974_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.berh.2018.02.002","volume":"31","author":"M Pardeo","year":"2017","unstructured":"Pardeo M, Bracaglia C, De Benedetti F. Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies. Best Pract Res Clin Rheumatol. 2017;31:505\u201316.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"974_CR26","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1073\/pnas.86.19.7547","volume":"86","author":"S Suematsu","year":"1989","unstructured":"Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989;86:7547\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"974_CR27","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1002\/art.22175","volume":"54","author":"F De Benedetti","year":"2006","unstructured":"De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006;54:3551\u201363.","journal-title":"Arthritis Rheum"},{"key":"974_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/jlb.59.4.489","volume":"59","author":"G Fantuzzi","year":"1996","unstructured":"Fantuzzi G, Dinarello CA. The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. J Leukoc Biol. 1996;59:489\u201393.","journal-title":"J Leukoc Biol"},{"key":"974_CR29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1084\/jem.180.4.1243","volume":"180","author":"E Fattori","year":"1994","unstructured":"Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994;180:1243\u201350.","journal-title":"J Exp Med"},{"key":"974_CR30","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3899\/jrheum.121389","volume":"40","author":"K Shimamoto","year":"2013","unstructured":"Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40:1074\u201381.","journal-title":"J Rheumatol"},{"key":"974_CR31","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody. Clin Pharmacokinet. 2012;51:e1-18.","journal-title":"Clin Pharmacokinet"},{"key":"974_CR32","doi-asserted-by":"publisher","first-page":"894846","DOI":"10.3389\/fped.2022.894846","volume":"10","author":"MM Kostik","year":"2022","unstructured":"Kostik MM, Isupova EA, Belozerov K, Likhacheva TS, Suspitsin EN, Raupov R, et al. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis. Front Pediatr. 2022;10:894846.","journal-title":"Front Pediatr"},{"key":"974_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12969-021-00510-8","volume":"19","author":"E Lainka","year":"2021","unstructured":"Lainka E, Baehr M, Raszka B, Haas JP, H\u00fcgle B, Fischer N, et al. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry. Pediatr Rheumatol Online J. 2021;19:38.","journal-title":"Pediatr Rheumatol Online J"},{"key":"974_CR34","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","volume":"37","author":"J Sota","year":"2018","unstructured":"Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018;37:2233\u201340.","journal-title":"Clin Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-024-00974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-024-00974-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-024-00974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:08:02Z","timestamp":1710821282000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-024-00974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1186\/s12969-024-00974-4","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Children\u2019s Hospital of Nanjing Medical University (approval number: 202211257-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}